1![LUMIZYME (alglucosidase alfa) for Injection LUMIZYME (alglucosidase alfa) for Injection](https://www.pdfsearch.io/img/eb91eba67f593dc65669ec9321c35a6b.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2010-05-26 09:39:24
|
---|
2![HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INTEGRILIN safely and effectively. See full prescribing information for INTEGRILIN. ® HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INTEGRILIN safely and effectively. See full prescribing information for INTEGRILIN. ®](https://www.pdfsearch.io/img/cfe7c44ffe465367e27d36896a7eca11.jpg) | Add to Reading ListSource URL: www.merck.comLanguage: English - Date: 2015-03-26 19:23:33
|
---|
3![A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery](https://www.pdfsearch.io/img/6fa4be86e065a990eef61b65e45a7ef5.jpg) | Add to Reading ListSource URL: www.thrombosisjournal.comLanguage: English |
---|
4![Reprint from January 8, 2007 BioCentury THE BERNSTEIN REPORT ARTICLE REPRINT Reprint from January 8, 2007 BioCentury THE BERNSTEIN REPORT ARTICLE REPRINT](https://www.pdfsearch.io/img/6ac2abfb077a963d420f22d80e6dccc2.jpg) | Add to Reading ListSource URL: www.cytokinetics.comLanguage: English - Date: 2008-03-07 11:41:50
|
---|
5![PRESS RELEASE Sanofi Provides Update on Phase 3 Studies of Two Investigational Compounds Paris, France - June 3, [removed]Sanofi (EURONEXT: SAN and NYSE: SNY) today announced topline results of two Phase 3 clinical studie PRESS RELEASE Sanofi Provides Update on Phase 3 Studies of Two Investigational Compounds Paris, France - June 3, [removed]Sanofi (EURONEXT: SAN and NYSE: SNY) today announced topline results of two Phase 3 clinical studie](https://www.pdfsearch.io/img/200b4841d3dbe3864e862a700d5a8943.jpg) | Add to Reading ListSource URL: en.sanofi.comLanguage: English - Date: 2014-10-09 15:26:45
|
---|
6![European Heart Journal[removed], 239–246 doi:[removed]euhj[removed], available online at http://www.idealibrary.com on Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous cor European Heart Journal[removed], 239–246 doi:[removed]euhj[removed], available online at http://www.idealibrary.com on Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous cor](https://www.pdfsearch.io/img/e81cb4423bb7993ee846827324df8cbc.jpg) | Add to Reading ListSource URL: eurheartj.oxfordjournals.orgLanguage: English - Date: 2015-04-09 11:57:27
|
---|
7![HIGHLIGHTS OF PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION](https://www.pdfsearch.io/img/bf12eb7fe152604cff8ddef013c5e09a.jpg) | Add to Reading ListSource URL: www.aldurazyme.comLanguage: English - Date: 2014-03-27 12:54:22
|
---|
8![Oprelvekin, (Neumega) Genetics Institute, Inc. Oprelvekin, (Neumega) Genetics Institute, Inc.](https://www.pdfsearch.io/img/cf1421fbf568e5c960c6bf663b7ff60b.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
9![NovoSeven Coagulation Factor VIIa (Recombinant) NovoSeven Coagulation Factor VIIa (Recombinant)](https://www.pdfsearch.io/img/f9fbcaf89064e32979035abfe1aacf40.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
10![Oprelvekin, (Neumega) Genetics Institute, Inc. Oprelvekin, (Neumega) Genetics Institute, Inc.](https://www.pdfsearch.io/img/f6cdc3bb578a64ac1f010731be4bb5a4.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|